Humanigen Inc (HGEN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Humanigen Inc (HGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013994
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Humanigen Inc(Humanigen) formerly known as KaloBios Pharmaceuticals Inc, is a development stage biopharmaceutical company that develops medicines for neglected and rare diseases. The company offers benznidazole, a nitroimidazole derivative used for the treatment of Chagas disease, a parasitic infection caused due to protozoan organism called Trypanosoma cruzi. Ifabotuzumab(anti-EphA3) and Lenzilumab(anti-GM-CSF), recombinant monoclonal antibodies, used for the treatment of solid tumors and their micro environment; and certain hematologic malignancies such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML), respectively.The company has developed the recombinant monoclonal antibodies using its proprietary drug discovery technology called Humaneered. Humanigen is headquartered in Brisbane, California, the US.

Humanigen Inc (HGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Humanigen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Humanigen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Humanigen Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
KaloBios Pharma Acquires Benznidazole Program from Savant Neglected Diseases 10
Venture Financing 11
KaloBios Pharma Raises USD12.2 Million in Venture Financing 11
Kalobios Pharma Raises Additional US$3 Million In Series E Financing 12
Equity Offering 13
Humanigen Plans to Raise up to USD15 Million in Private Placement of Shares 13
KaloBios Pharma Plans to Raise Funds through Public Offering of Shares 14
KaloBios Pharma to Raise Funds through Private Placement of Shares, upon Exercise of Warrant 15
KaloBios Pharma Raises USD8.8 Million in Private Placement of Shares 16
KaloBios Pharma Completes Public Offering Of Shares For US$34.5 Million 17
KaloBios Pharma Completes IPO For US$70 Million 19
Acquisition 21
Martin Shkreli Led Consortium Acquires 70% Stake in KaloBios Pharma 21
Humanigen Inc – Key Competitors 22
Humanigen Inc – Key Employees 23
Humanigen Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Corporate Communications 25
Aug 28, 2017: Humanigen Appoints Chief Financial Officer 25
Jan 12, 2016: KaloBios Pharmaceuticals Withdraws Appeal on Nasdaq Delisting 26
Jan 11, 2016: KaloBios Pharmaceuticals Announces Board Changes and New Appointments 27
Product News 28
04/11/2016: KaloBios Announces New Product Pricing Model 28
04/06/2017: Benznidazole on Track in Progress to IND and NDA Submissions 29
Product Approvals 30
Jul 11, 2017: KaloBios Receives Orphan Drug Designation for Benznidazole in the Treatment of Chagas Disease 30
Jun 27, 2017: Benznidazole IND for Chagas Disease Receives Clearance by FDA 31
May 30, 2017: KaloBios Submits IND Application for Benznidazole to FDA 32
Jan 05, 2017: KaloBios Announces Positive Guidance from FDA for Benznidazole 33
Dec 12, 2016: KaloBios Completes Meeting with FDA for Benznidazole 34
Clinical Trials 35
Aug 08, 2017: Humanigen Announces Completion of Benznidazole Bioavailability Study 35
Other Significant Developments 36
Jul 27, 2017: KaloBios To Change Company Name To Humanigen 36
Aug 29, 2016: KaloBios Announces Martin Shkreli’s Sale Of His Stake In The Company 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Humanigen Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Humanigen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Humanigen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Humanigen Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Humanigen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
KaloBios Pharma Acquires Benznidazole Program from Savant Neglected Diseases 10
KaloBios Pharma Raises USD12.2 Million in Venture Financing 11
Kalobios Pharma Raises Additional US$3 Million In Series E Financing 12
Humanigen Plans to Raise up to USD15 Million in Private Placement of Shares 13
KaloBios Pharma Plans to Raise Funds through Public Offering of Shares 14
KaloBios Pharma to Raise Funds through Private Placement of Shares, upon Exercise of Warrant 15
KaloBios Pharma Raises USD8.8 Million in Private Placement of Shares 16
KaloBios Pharma Completes Public Offering Of Shares For US$34.5 Million 17
KaloBios Pharma Completes IPO For US$70 Million 19
Martin Shkreli Led Consortium Acquires 70% Stake in KaloBios Pharma 21
Humanigen Inc, Key Competitors 22
Humanigen Inc, Key Employees 23

★海外企業調査レポート[Humanigen Inc (HGEN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Greenphire Inc:医療機器:M&Aディール及び事業提携情報
    Summary Greenphire Inc (Greenphire) is a provider of clinical trial payment solutions that offers patients reimbursement and site payments. The company’s products portfolio includes ClinCard, ConneXTS and eClinicalGPS. Its eClinicalGPS is a global site that facilitates accurate payment calculation, …
  • Group 1 Automotive, Inc.:企業のM&A・事業提携・投資動向
    Group 1 Automotive, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Group 1 Automotive, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • SRT Marine Systems plc (SRT):企業の財務・戦略的SWOT分析
    SRT Marine Systems plc (SRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Roland DG Corp (6789):企業の財務・戦略的SWOT分析
    Roland DG Corp (6789) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Heinzel Holding GmbH:企業の戦略的SWOT分析
    Heinzel Holding GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • EnBW Energie Baden-Wurttemberg AG (EBK):企業の財務・戦略的SWOT分析
    EnBW Energie Baden-Wurttemberg AG (EBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • BioCryst Pharmaceuticals Inc (BCRX)-製薬・医療分野:企業M&A・提携分析
    Summary BioCryst Pharmaceuticals Inc (BioCryst) designs, optimizes and develops small molecule drugs that block key enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary Angioedemaon. Biocryst integrat …
  • Munchener Ruckversicherungs-Gesellschaft AG (Munich Re):企業のM&A・事業提携・投資動向
    Munchener Ruckversicherungs-Gesellschaft AG (Munich Re) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Munchener Ruckversicherungs-Gesellschaft AG (Munich Re) Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes b …
  • Caladrius Biosciences Inc (CLBS)-医療機器分野:企業M&A・提携分析
    Summary Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc is a clinical stage development company that develops and manufactures cell therapy products. The company’s products are based on its proprietary technologies such as Dendritic Cell-Tumor Cell technology; CD34 technology; and T Regu …
  • Enerjisa Enerji Uretim AS-エネルギー分野:企業M&A・提携分析
    Summary Enerjisa Enerji Uretim A.S. (Enerjisa Enerji), a subsidiary of Enerjisa Enerji A.S, is an energy utility. The company generates electricity from wind, lignite coal, hydro, and natural gas sources. It owns and operates wind plants such as Canakkale in Mahmudiye, Dagpazari in Mut, and Balikesi …
  • Custodian & Allied Plc:企業の戦略・SWOT・財務分析
    Custodian & Allied Plc - Strategy, SWOT and Corporate Finance Report Summary Custodian & Allied Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Icelandair Group:企業の戦略・SWOT・財務情報
    Icelandair Group - Strategy, SWOT and Corporate Finance Report Summary Icelandair Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • United Parcel Service Inc (UPS):企業の財務・戦略的SWOT分析
    United Parcel Service Inc (UPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Europaeische Reiseversicherung AG:企業の戦略・SWOT・財務情報
    Europaeische Reiseversicherung AG - Strategy, SWOT and Corporate Finance Report Summary Europaeische Reiseversicherung AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Nisshinbo Holdings, Inc.:企業の戦略・SWOT・財務分析
    Nisshinbo Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nisshinbo Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Adamis Pharmaceuticals Corp (ADMP)-医療機器分野:企業M&A・提携分析
    Summary Adamis Pharmaceuticals Corp (Adamis), formerly Cellegy Pharmaceuticals Inc is a biopharmaceutical company that offers therapies. The company develops and commercializes products in the therapeutic areas of allergy and respiratory diseases. Its pipeline product, epinephrine pre-filled syringe …
  • United States Postal Service:企業の戦略的SWOT分析
    United States Postal Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Sany Heavy Industry Co Ltd (600031):企業の財務・戦略的SWOT分析
    Sany Heavy Industry Co Ltd (600031) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Hals-Development:企業の戦略・SWOT・財務情報
    Hals-Development - Strategy, SWOT and Corporate Finance Report Summary Hals-Development - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Acerus Pharmaceuticals Corp (ASP)-製薬・医療分野:企業M&A・提携分析
    Summary Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation, is a pharmaceutical company that develops, manufactures, markets and distributes innovative branded products. It focuses on men’s and women’s health. The company uses its proprietary drug delivery technology p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆